Novo-Nordisk A/S

48.36

+0.37920.79%

Volume:404.19K

Turnover:19.37M

Market Cap:214.00B

PE:14.22

High:49.46

Open:49.01

Low:47.36

Close:47.99

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NONOF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NONOF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NONOF\",,,,,undefined,":{"symbol":"NONOF","market":"US","secType":"STK","nameCN":"Novo-Nordisk A/S","latestPrice":48.3642,"timestamp":1754078400000,"preClose":47.985,"halted":0,"volume":404194,"delay":15,"floatShares":3170039129,"shares":4424720356,"eps":3.401716,"marketStatus":"Market Closed","change":0.3792,"latestTime":"08-01 16:00:00 EDT Delay","open":49.01,"high":49.46,"low":47.36,"amount":19367985.481399998,"amplitude":0.043764,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":3.401716,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":47.985,"volumeRatio":0.24164076156270747},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NONOF\",,,,,undefined,":{"symbol":"NONOF","floatShares":3170039129,"roa":"23.29%","roe":"88.12%","lyrEps":3.147662,"volumeRatio":0.24164076156270747,"shares":4424720356,"dividePrice":1.683166,"high":49.46,"amplitude":0.043764,"preClose":47.985,"low":47.36,"week52Low":47.25,"pbRate":"10.50","psRate":"4.80","week52High":141.19,"institutionHeld":0,"latestPrice":48.3642,"eps":3.401716,"divideRate":0.034802,"volume":404194,"delay":15,"ttmEps":3.401716,"open":49.01,"prevYearClose":85.897,"prevWeekClose":69.94,"prevMonthClose":47.985,"prevQuarterClose":69.48,"fiveDayClose":69.94,"twentyDayClose":69.49,"sixtyDayClose":66.2269},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NONOF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NONOF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549818342","title":"PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549818342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549818342?lang=en_us&edition=fundamental","pubTime":"2025-07-05 01:51","pubTimestamp":1751651460,"startTime":"0","endTime":"0","summary":"Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%.The recent pipeline setbacks have significantly hurt PRTA’s growth prospects.Last month, PRTA announced that it is reducing its workforce by 63% to lower its operating costs, essential to support its remaining wholly owned programs, its obligations to partnered programs and its anticipated business development activities.As a result of this restructuring, PRTA also revised its annual guidance. The company expects its 2025 net cash burn from operating and investing activities to be in the range of $170- $178 million. PRTA expects approximately $298 million  in cash, cash equivalents and restricted cash. Net loss is now estimated between $240 million and $248 million .The estimated loss for 2025 includes $105-$110 million of operating expenses associated with birtamimab and the company's reorganization, including research, development, manufacturing and pre-commercial expenses, s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prta-dives-53-5-ytd-175100124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","LU0882574055.USD","LU0237698245.USD","LU2125154935.USD","BK4139","LU1670710661.SGD","LU0061475181.USD","LU1291159041.SGD","LU0114720955.EUR","LU2242652126.USD","BMY","IE00BFXG1179.USD","LU1571399168.USD","IE00BJT1NW94.SGD","LU1261432733.SGD","IE00B2B36J28.USD","LU1670711040.USD","IE0009355771.USD","LU0267386448.USD","LU1868836914.USD","LU2360032135.SGD","LU1670710588.SGD","LU0321505868.SGD","LU1323610961.USD","LU1032466523.USD","LU0154236417.USD","LU0868494617.USD","LU1868836591.USD","PRTA","LU0321505439.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","LU2242646821.SGD","LU0225284248.USD","RHHBY","03165","LU1093756325.SGD","LU0306806265.USD","LU1868837136.USD","LU0456855351.SGD","LU1093756168.USD","LU1868837300.USD","IE00BSNM7G36.USD","LU1868836757.USD","BK4581","LU1989771016.USD","BK4588","LU0306807586.USD","NONOF"],"gpt_icon":1},{"id":"2549342816","title":"Are You Looking for a High-Growth Dividend Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549342816","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549342816?lang=en_us&edition=fundamental","pubTime":"2025-07-04 23:45","pubTimestamp":1751643902,"startTime":"0","endTime":"0","summary":"Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.Headquartered in Bagsvaerd, Novo Nordisk  is a Medical stock that has seen a price change of -19.59% so far this year. Currently paying a dividend of $0.82 per share, the company has a dividend yield of 2.37%. In comparison, the Large Cap Pharmaceutical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/looking-high-growth-dividend-stock-154502620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU1093756325.SGD","NONOF","LU1093756168.USD","BK4007","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4532","BK4599","NVO","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2549342890","title":"Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549342890","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549342890?lang=en_us&edition=fundamental","pubTime":"2025-07-04 21:53","pubTimestamp":1751637180,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide -based therapies, Wegovy for obesity and Ozempic for type II diabetes . While maintaining its leadership in metabolic diseases, the company is also making significant efforts to diversify its portfolio, particularly in rare blood disorders.NVO’s key marketed hemophilia therapies include NovoSeven and Esperoct, which generate incremental revenues for the company. NovoSeven is approved in the United States and the EU for several bleeding disorders, including hemophilia A or B with inhibitors, Factor VII deficiency, and Glanzmann’s thrombasthenia. Esperoct is approved for treating Hemophilia A in both adults and children.Another large-cap drugmaker,Merck MRK, is also making significant efforts in broadening its therapeutic reach beyond core revenue drivers. MRK’s flagship oncology drug Keytruda, which accounts for nearly half of its total revenues, is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisks-rare-disease-bets-135300669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","IE00BLSP4239.USD","MRK","LU1061106388.HKD","LU0265550359.USD","SG9999014567.USD","LU0098860793.USD","LU1291159041.SGD","LU2361044865.SGD","LU1066051811.HKD","SG9999013999.USD","LU0965509101.SGD","BK4516","LU1035775433.USD","SG9999015341.SGD","LU2746668461.USD","LU0097036916.USD","LU0114720955.EUR","LU1037948897.HKD","IE0009355771.USD","SGXZ99366536.SGD","LU0417517546.SGD","LU0385154629.USD","LU1162221912.USD","LU0882574139.USD","LU0006306889.USD","SGXZ31699556.SGD","LU2461242641.AUD","LU2417539215.USD","LU1868836757.USD","NONOF","LU2491050071.SGD","LU1064131342.USD","GLP","LU2491049909.HKD","LU1699723380.USD","IE00BSNM7G36.USD","NVO","LU1066051498.USD","LU0208291251.USD","LU2471134796.USD","SG9999014559.SGD","LU0070302665.USD","LU0154236417.USD","LU2237443622.USD","LU1868837136.USD","LU1551013425.SGD","LU0882574055.USD","LU2237443382.USD"],"gpt_icon":1},{"id":"2549334281","title":"Can CVS Sustain Pharmacy & Consumer Wellness Gains Through Year-End?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549334281","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549334281?lang=en_us&edition=fundamental","pubTime":"2025-07-04 20:44","pubTimestamp":1751633040,"startTime":"0","endTime":"0","summary":"CVS Health’s CVS Pharmacy and Consumer Wellness  segment has seen steady growth in recent months, with revenues up 11.1% year over year in the first quarter of 2025. Performance was supported by seasonal trends, including the impact of high vaccine demand and a longer-than-usual flu season. The key question now is whether CVS can hold this momentum through the rest of fiscal 2025.The company is likely to continue benefiting from a favorable pharmacy drug mix, boosted by the rising demand for high-cost branded GLP-1 medications. A key development is CVS Pharmacy’s inclusion in Novo Nordisk’s NovoCare pharmacy network, enabling it to expand Wegovy’s access at more than 9,000 community health locations nationwide. Further, the implementation of its pharmacy reimbursement model, CostVantage, positions the PCW business for improved future results by eliminating some of the cross-subsidization that exists in the market. Effective Jan. 1, 2025, all commercial prescriptions dispensed through C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-sustain-pharmacy-consumer-wellness-124400448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0310799852.SGD","LU2505996681.GBP","LU2430703178.SGD","LU1815333072.USD","LU2097829019.USD","LU2361044949.HKD","CVS","LU0096362180.USD","LU1066051498.USD","IE00B7SZLL34.SGD","LU0208291251.USD","WBA","NONOF","BK4597","IE00BSNM7G36.USD","LU1066051811.HKD","LU1699723380.USD","LU0738911758.USD","BK4581","LU0072461881.USD","BK4155","LU0314104364.USD","LU0070302665.USD","BK4533","WMT","LU1267930490.SGD","LU2361044865.SGD","LU2125154935.USD","LU2461242641.AUD","LU0256863902.USD","LU0265550359.USD","LU0061475181.USD","LU0211331839.USD","LU1064131342.USD","LU1116320737.USD","LU2746668461.USD","LU1003077747.HKD","LU2505996509.AUD","BK4128","LU0149725797.USD","LU2360032135.SGD","LU0417517546.SGD","LU0321505439.SGD","LU1366192091.USD","LU2750360997.AUD","LU2750360641.GBP","BK4196","LU0289960550.SGD","LU2471134796.USD","LU0211327993.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NONOF\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"NONOF","amount":7.9,"announcedDate":"2025-02-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743168600000,"name":"Novo-Nordisk A/S","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-31","currency":"DKK","dateTimestamp":1743134400000,"payDate":"2025-04-01"},{"date":"2024-08-15","symbol":"NONOF","amount":3.5,"announcedDate":"2024-08-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-16","defaultRemindTime":1723728600000,"name":"Novo-Nordisk A/S","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-19","payableDate":"2024-08-16","currency":"DKK","dateTimestamp":1723694400000,"payDate":"2024-08-19"},{"date":"2024-05-02","symbol":"NONOF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714636800000,"name":null,"time":"","dateTimestamp":1714622400000,"actualEps":null},{"date":"2024-03-22","symbol":"NONOF","amount":6.4,"announcedDate":"2024-01-31","type":"dividend","market":"US","newRecordDate":"2024-03-25","defaultRemindTime":1711114200000,"name":"Novo-Nordisk A/S","recordDate":"2024-03-26","payableDate":"2024-03-25","currency":"DKK","dateTimestamp":1711080000000,"payDate":"2024-03-26"},{"market":"US","date":"2024-01-31","symbol":"NONOF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706677200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NONOF\",market:\"US\",,,undefined,":[{"executeDate":"2019-03-22","recordDate":"2019-03-25","paymentDate":"2019-03-26","value":5.15,"currency":"DKK"},{"executeDate":"2019-08-16","recordDate":"2019-08-19","paymentDate":"2019-08-20","value":3,"currency":"DKK"},{"executeDate":"2020-03-27","recordDate":"2020-03-30","paymentDate":"2020-03-31","value":5.35,"currency":"DKK"},{"executeDate":"2020-08-14","recordDate":"2020-08-17","paymentDate":"2020-08-18","value":3.25,"currency":"DKK"},{"executeDate":"2021-03-26","recordDate":"2021-03-29","paymentDate":"2021-03-30","value":5.85,"currency":"DKK"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NONOF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.4074,"hold":0.4074,"sell":0.037,"strongSell":0.037,"meanLabel":"BUY","meanPercent":0.4074,"analysts":27,"updateTime":1754020800000}}}